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mon sustained cardiac arrhythmia. It is associated with increased risk
for stroke mainly due to cardiac embolism from the left atrial
appendage (LAA). Occlusion of the LAA by means of a device
represents a valid alternative to oral anticoagulation, mainly in
patients who cannot tolerate this therapy because of a high bleeding
risk. Recent data on the endocardial device WATCHMAN show
encouraging results for this patient population in terms of stroke risk
reduction compared to the expected rate as well as in terms of implant
success. This article reviews all relevant publications related to the
main surgical and transcatheter devices used for LAA closure (LAAC).
METHODS/RESULTS PROTECT-AF, the ﬁrst prospective randomized
trial conducted on this technique, showed that LAA occlusion using
the WATCHMAN was noninferior to warfarin for a combined end-
point in patients with nonvalvular AF. There is a lack of large-scale
randomized trials on long-term stroke risk in patients submitted to
LAAC. Most studies are relatively small and focus on the comparison
of different surgical techniques with regard to complete/incom-
plete closure success. More recently, PROTECT-AF long-term resultsDr. Camm is a consultant for and an advisor to Medtronic, St. Jude
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rior to warfarin in terms of efﬁcacy.
CONCLUSION This review concludes that it is now appropriate to
consider these techniques for patients with AF who are at high risk
for stroke for whom effective conventional or novel anticoagulant
therapy is not available or who present problems in managing drug
treatment.
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Most strokes in patients with atrial ﬁbrillation (AF) result
from thrombus formation in the left atrial appendage (LAA).
Beinart et al1 and Thambidorai et al2 found up to 90% of
thrombi in the LAA in patients undergoing cardioversion.
The LAA lies anteriorly in the atrioventricular sulcus in
close proximity to the left circumﬂex artery, the left phrenic
nerve, and the left pulmonary veins. The shape of the LAA is
variable; four main morphologies can be identiﬁed: “cactus,”
“chicken wing,” “windsock,” and “cauliﬂower.” LAA mor-
phology appears to be associated with different degrees ofthromboembolic risk.3 Patients with non–chicken wing LAA
morphology are signiﬁcantly more likely to have an embolic
event, even after controlling for comorbidities and CHADS2
score.3,4
In addition to LAA structure and function, the size of the
left atrium (LA), left ventricular function, disorders of coag-
ulation,5,6 endothelial dysfunction, platelet activation,7–10 and
many comorbid conditions play a relevant role in stroke risk.
Several scores have been developed and recommended in
clinical practice to determine whether anticoagulation therapy
should be prescribed for prevention of ischemic AF-related
stroke.11 CHADS2 and CHA2DS2-VASc, the two most
popular scores for assessing the risk of ischemic stroke, are
recommended by guidelines; they take into consideration the
comorbid conditions of the patient with AF.12–14
A large proportion of patients with indications for oral
anticoagulation (OAC) either are never prescribed the
therapy15 or stop the treatment because of side effects,
advice from their physicians, or their own decisions related
to quality of life or bleeding concerns. In the RE-LYhttp://dx.doi.org/10.1016/j.hrthm.2013.11.030
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apy) trial, 10% and 17% of patients treated with warfarin
stopped the treatment at 1 and 2 years, respectively.16
Similarly, 15% and 16% of patients treated with dabigatran
110 mg stopped the treatment at 1 and 2 years, respectively
(21% if considering dabigatran 150 mg).16 In the ARISTO-
TLE (Apixaban for Reduction in Stroke and Other Throm-
boembolic Events in Atrial Fibrillation) trial, 25% and 28%
of patients discontinued apixaban and warfarin, respectively,
during the trial.17 Similarly, in the ROCKET-AF (Rivarox-
aban Once daily oral direct factor Xa inhibition Compared
with vitamin K antagonism [VKA] for prevention of stroke
and Embolism Trial in AF) trial, 24% and 22% of patients
stopped the treatment with rivaroxaban and warfarin,
respectively, during the trial.18 All patients who discontinue
OAC are then treated with nothing or with antiplatelet
therapy, unless the side effect is speciﬁc to a particular
anticoagulant and therefore the patient becomes exposed to a
high thromboembolic risk.
Warfarin and even more so the new OACs play a relevant
role in reducing the thromboembolic risk associated with AF.
On the other hand, inconsistent and inappropriate use, food–
drug (VKA only) and drug–drug (VKA and novel OACs)
interactions, and other side effects, particularly bleeding, must
be considered when treatment based on anticoagulants is
prescribed. Furthermore, as discussed earlier, some patients
cannot be treated with anticoagulants because they have
contraindications or are intolerant. Therefore, additional
approaches to preventing AF-related stroke are needed.
Bleeding is also a clinically relevant adverse event in
patients treated with antithrombotic therapy, and the physi-
cian must balance this risk with the risk of thromboembolism
when deciding about OAC in patients with AF. The risk of
bleeding can be determined using, for example, the HAS-
BLED19 or ATRIA20 score. The 2012 update of the Euro-
pean Society of Cardiology (ESC) guidelines recommends
using the HAS-BLED score to assess bleeding risk in AF
patients, with a score Z3 indicating high risk.
For all these reasons, surgical and transcatheter techni-
ques have been explored to reduce the risk of stroke in
persons with AF by excluding or occluding the LAA. Several
methods can be used to close the appendage: direct suture
during concomitant cardiac surgery, epicardial exclusion by
stapling or clips, or endovascular occlusion by percutaneous
application.Nonpharmacologic treatments
The surgical approach
Amputation or obliteration of the LAA is considered in two
possible situations: (1) as an additional procedure to either
unrelated surgery or surgical MAZE procedures done
speciﬁcally for management of AF, and (2) as an isolated
closed chest (e.g., thoracoscopic) procedure.21
However, there is a lack of large-scale randomized trials
on long-term stroke risk in patients submitted to surgical
closure of the LAA. Most studies are relatively small andfocus on the comparison of different surgical techniques with
regard to complete/incomplete closure success. A larger
randomized trial (Left Atrial Appendage Occlusion Study
III [LAAOS III]) has been designed and is currently
recruiting participants to evaluate the safety and efﬁcacy of
LAA removal in patients with AF undergoing heart surgery
(Table 2).
Conclusions about stroke prevention by LAA exclusion
or excision through surgery are still controversial.The transcatheter approach
A technique that is intermediate between the surgical
approach and the transcatheter approach is the endocardial/
epicardial technique based on the LARIAT (SentreHEART
Inc, Redwood City, CA) device.22,23 The device is used for
LAA ligation through a catheter (Figure 1D). Initial data on
humans reported 96% implant success, and of the patients
undergoing transesophageal echocardiography (TEE) at
1 year, there was 98% complete LAA closure (LAAC),
including the patients with previous leaks.22 Initial experi-
ence in the United States reported encouraging results in
25 patients, with 100% implant success and no strokes.23
To date, four devices with a purely endocardial approach
have been investigated for LAA occlusion: the percutaneous
LAA transcatheter occlusion (PLAATO) system (eV3, Ply-
mouth, MN; Figure 1A), the Amplatzer cardiac plug (ACP)
(St. Jude Medical, Minneapolis, MN; Figure 1B), the
WATCHMAN device (Boston Scientiﬁc, Maple Grove,
MN; (Figure 1C), and the Wavecrest System (Coherex
Medical, Salt Lake City, UT; very little information
available).24
All systems are delivered percutaneously through trans-
septal access to the LA.24 Preprocedural evaluation of the LA
and LAA, exclusion of thrombus, veriﬁcation of placement,
and evaluation of postprocedural pericardial effusion require
skilled ﬂuoroscopic and TEE coordination.25 Cardiac mag-
netic resonance may offer some imaging advantages and
help to select the type and size of device.26,27 Computed
tomography may also be a valid option to assist preoperative
planning of LAA closure device placement.28
The PLAATO experience showed that, in a nonrandom-
ized cohort, device implantation was feasible and safe, and,
when compared with the historical stroke risk estimated
using the CHADS2 score, apparently cut the stroke rate by
40% to 65% in higher-risk AF patients. The PLAATO device
has been discontinued for commercial reasons.
The ACP is a self-expanding device constructed from a
nitinol mesh and polyester patch developed on the basis of
Amplatzer double-disk septal occluders.29 Patients
implanted with this device are maintained on dual antipla-
telet therapy with 1 to 3 months of clopidogrel followed by at
least 5 months of aspirin. Limited data are available for the
ACP, and the only randomized clinical trial that evaluated
the device against optimal anticoagulation medical therapy
(warfarin and dabigatran) is now underway.30
Figure 1 A: PLAATO. B: Amplatzer cardiac plug. C: WATCHMAN device, D: LARIAT. (From Chatterjee S, Alexander JC, Pearson PJ, Feldman T. Left
atrial appendage occlusion: lessons learned from surgical and transcatheter experiences. Reproduced from Ann Thorac Surg 2011;92:2283–2292.)
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successfully implanted in 96% (137/143) of patients in
whom LAA closure was attempted. Serious complications
were reported in 10 (7.0%) patients (ischemic stroke, device
embolization, signiﬁcant pericardial effusions). Minor com-
plications were insigniﬁcant pericardial effusions, transient
myocardial ischemia, and loss of the implant in the venous
system. Interim data from the ACP European postmarket
registry showed similar procedural success (96.5%) with no
device embolization during the implant procedure.31
Procedure-related adverse events were not signiﬁcantly
changed compared to the previous data (3 signiﬁcant
pericardial effusion, 3 device embolization, 1 cardiac perfo-
ration, 1 arteriovenous ﬁstula). Three cases of thrombus on
the device and one case of late device embolization were
detected during the post 7-day follow-up.
The WATCHMAN device has a porous polyethylene
terephthalate membrane on the proximal face of a self-
expanding nitinol cage with ﬁxation barbs for secure
implantation within the LAA. The efﬁcacy of this device
has been evaluated in a large-scale trial, the only randomized
study available at the present time for analyzing LAA closure
by means of devices—WATCHMAN Left Atrial Appendage
System for Embolic Protection in Patients with Atrial
Fibrillation (PROTECT-AF). The study randomized 707
patients with nonvalvular AF from 59 sites worldwide 2:1to the WATCHMAN device. The study was designed to
assess the noninferiority of the device against chronic
warfarin therapy.32 Patients Z18 years with paroxysmal,
persistent, or permanent nonvalvular AF were eligible for
enrollment if they had a CHADS2 risk scoreZ1. Exclusion
criteria included contraindications to warfarin, comorbidities
other than AF that required chronic warfarin use, LAA
thrombus, patent foramen ovale with atrial septal aneurysm
and right-to-left shunt, mobile aortic atheroma, and sympto-
matic carotid artery disease. Patients allocated to the
intervention group were treated postimplant with warfarin
for 45 days to facilitate device endothelialization, with the
warfarin discontinued if 45-day TEE showed either complete
LAAC or acceptable residual peri-device ﬂow (jeto5 mm in
width) (Figure 2). After warfarin treatment was stopped,
once-daily clopidogrel (75 mg) and aspirin (81–325 mg)
were prescribed until completion of 6-month follow-up visit,
then aspirin alone was continued indeﬁnitely. Patients in the
control group received warfarin for the duration of the study,
with monitoring of the target international normalized ratio
(INR) between 2.0 and 3.0 at least every 2 weeks for 6
months and at least once per month thereafter. At 1.065
patient-years of follow-up, the trial showed that the efﬁcacy
of a strategy for percutaneous closure of the LAA was
noninferior to that of chronic warfarin therapy (Figure 3),
providing evidence for the role of the LAA in stroke
Figure 2 Endothelialization of the WATCHMAN device 9 months after
the procedure. (From Sick PB, Schuler G, Holmes D, et al. Initial worldwide
experience with the WATCHMAN left atrial appendage system for stroke
prevention in atrial ﬁbrillation. Reproduced from J Am Coll Cardiol
2007;49:1490–1495.)
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group, the therapeutic INR range was achieved 66% of the
time despite close INR follow-up. Although the advent of
new OACs may improve the quality of medical treatment,
the safety and efﬁcacy of the device for LAA closure were
well assessed in comparison with warfarin by this trial.
The inﬂuence of the operator’s experience on the safety of
percutaneous LAAC was assessed in an analysis of patients
from the PROTECT-AF trial who underwent attempted
device LAAC (n ¼ 542 patients) and from a subsequent
nonrandomized registry of patients undergoing WATCH-
MAN implantation (Continued Access Protocol [CAP]
Registry; n ¼ 460 patients).33 The safety end-point included
bleeding and procedure-related events (pericardial effusion,
stroke, device embolization). There was a signiﬁcant decline
in the rate of procedure or device-related safety events withinFigure 3 Kaplan-Meier curves of incidence of study end-points in intervention an
Sick P, et al; PROTECTAF Investigators. Percutaneous closure of the left atrial app
ﬁbrillation: a randomized non-inferiority trial. Reproduced from Lancet 2009;3747 days of the procedure across the two studies, with 7.7% and
3.7% of patients, respectively, experiencing events (with
reduction of 52%, P ¼ .007), and, between the ﬁrst and
second halves of PROTECT-AF and CAP, with 10.0%,
5.5%, and 3.7% of patients, respectively, experiencing
events (P¼ .006). These data have shown that complications
associated with WATCHMAN implantation are typically
clustered early in the periprocedural period and signiﬁcantly
decrease in frequency with operator experience.
Preliminary results of the Prospective Randomized Eval-
uation of the WATCHMAN LAA Closure Device In Patients
with Atrial Fibrillation Versus Long Term Warfarin Therapy
(PREVAIL) showed other encouraging data in terms of safety
for the procedure performed with the WATCHMAN device.
Implant success was 95%, and safety events (deﬁned as acute
[i.e., within 7 days] occurrence of death, ischemic stroke,
systemic embolism, and procedure- or device-related compli-
cations requiring major cardiovascular or endovascular inter-
vention) occurred in only 2.2% of patients. Of interest, a
minimum of 20% of subjects were enrolled at new centers,
and 25% of subjects were enrolled by new operators.34
Recently presented long-term follow-up data of the
PROTECT-AF trial (4-year follow-up) have demonstrated
a 40% relative risk reduction (combined end-point of all
strokes, cardiovascular, or unexplained death and systemic
embolism) in the WATCHMAN group compared to the
control group (observed primary efﬁcacy event rate 2.3%
and 3.8%, respectively), with 96% posterior probability of
superiority. Secondary analysis also showed a statistical
superiority in all-cause mortality (34% relative risk reduc-
tion) and cardiovascular mortality (60% relative risk reduc-
tion).35 Long-term efﬁcacy from PROTECT-AF coupled
with safety results of PREVAIL and CAP provide strong
evidence that WATCHMAN, the most studied device for
LAAC and the only one with randomized and long-term
clinical data, may be a viable alternative to chronic warfarin
therapy for stroke reduction in nonvalvular AF patients.d control groups for the PROTECT-AF trial. (From Holmes DR, Reddy VY,
endage versus warfarin therapy for prevention of stroke in patients with atrial
:534–542.32)
Table 1 CHADS2, CHA2DS2-VASc, and HAS-BLED scores for ischemic stroke and bleeding risk stratiﬁcation
CHADS2 CHA2DS2-VASc HAS-BLED
Risk Factor Points Risk Factor Points Risk Factor Points
C Congestive heart failure 1 C Congestive heart failure 1 H Hypertension 1
H Hypertension 1 H Hypertension 1 A Abnormal liver and renal function (1 point each) 1 or 2
A AgeZ75 years 1 A2 AgeZ75 years 2 S Stroke 1
D Diabetes mellitus 1 D Diabetes mellitus 1 B Bleeding 1
S2 Previous stroke or TIA 2 S2 Previous stroke or TIA 2 L Labile INR 1
V Vascular disease 1 E Elderly (age465) 1
A AGE 65-74 years 1 D Drugs or alcohol (1 point each) 1 or 2
Sc Sex (female gender) 1
Hypertension is a common factor only if it relates to an ongoing disease and not to a history of the same.
Common factors are shown in bold.
INR ¼ international normalized ratio; TIA ¼ transient ischemic attack.
Heart Rhythm, Vol 11, No 3, March 2014518On the other hand, many AF patients at highest risk for
embolic stroke may also have the greatest risk for hemor-
rhagic complications of anticoagulation (Table 1). Thus,
patients with contraindications to OAC might beneﬁt from
LAAC; this was the objective of the ASA Plavix Registry
(ASAP) study, which enrolled patients with contraindica-
tions to chronic warfarin treatment.36 This prospective
registry enrolled 150 patients with nonvalvular AF,
CHADS2 scoreZ1 (mean 2.8 1.2), and a contraindication
to warfarin use. Postimplant, patients were discharged taking
clopidogrel for 6 months and aspirin lifelong. At mean
follow-up of 14.4  8.6 months and 98% 1-year follow-up
compliance, there were four strokes; ﬁve pericardial effu-
sions, of which only two with tamponade required percuta-
neous drainage; and six instances of device-related thrombus
by TEE, only one of which resulted in a clinical sequela
[ischemic stroke]). The observed rate of ischemic stroke was
1.7% (Figure 4), corresponding to a 77% reduction from the
expected event rate in patients with a similar CHADS2 score
treated with aspirin alone (7.3%) and a 64% reduction vs
aspirin and lifelong clopidogrel (5.0%). The success rate of
WATCHMAN implantation was 142 of 150 patientsFigure 4 Observed rate of ischemic stroke in the ASAP registry (1.7%)
compared to the expected event rate in patients with a similar CHADS2 score
treated with aspirin (7.3%) and if clopidogrel also was used (5.0%). (From
Reddy VY,Möbius-Winkler S, Sievert H, et al. Left atrial appendage closure
with the Watchman device in patients with a contraindication for oral
anticoagulation: ASA Plavix Feasibility Study with Watchman Left Atrial
Appendage Closure Technology (ASAP Study). Reproduced from J Am
Coll Cardiol 2013;61:2551–2556.36).(94.7%). The authors concluded that WATCHMAN implan-
tation without a warfarin transition might be safe and
effective in AF patients with contraindications to even
short-term OAC.Conclusion
The endocardial approach may be considered a safe and
effective alternative to OAC, especially when this treatment
is contraindicated or when OAC may place patients at high
risk for major bleeding. Noninferiority to standard anti-
coagulant treatment of LAAC with the WATCHMAN
device has been proven by the PROTECT-AF trial.32 Further
clinical data will help to reinforce this result by enlarging the
population of patients evaluated as well as by having longer
follow-up data on patients treated with percutaneous devices
in general. Further information is needed with regard to the
efﬁcacy and safety of LAAC in comparison to novel
OAC drugs.
Current European guidelines recommend treating patients
at risk for stroke with the appropriate antithrombotic therapy
depending on the risk factors for stroke as evaluated by the
CHA2DS2-VASc score and the risk of bleeding as assessed
by the HAS-BLED score.12 Physicians should pay attention
to managing those patients with contraindications to OAC orFigure 5 Main conditions when left atrial appendage closure (LAAC)
alternative can be evaluated. TIA ¼ transient ischemic attack.
Table 2 Ongoing trials on LAA occlusion/excision
Trial
Expected
no. of
patients Intervention Condition Study design Primary end-point Status Start date
Estimated
completion date
LAAOSIII 4700 LAA occlusion (suture
and/or surgical
stapler)
AF and cardiac
surgery with
cardiopulmonary
bypass
Randomized Stroke or systemic arterial embolism Recruiting July 2012 May 2019
Safety and Efﬁcacy of Left Atrial
Appendage Occlusion Devices
150 Device: LARIAT AF Observational model:
Case control
Effect of LAA occlusion by LARIAT device Recruiting May 2012 May 2018
Device: WATCHMAN Effect of LAA occlusion by WATCHMAN
device
ELIGIBLE 120 LAA occlusion with
Amplatzer device
AF Randomized Combined overall mortality, major
bleeding, stroke, or procedure-related
complications
Recruiting February 2012 July 2014
ISAR-AF 120 Percutaneous closure
of LAA by a closure
device (not
speciﬁed)
AF Randomized Composite endpoint of all-cause death,
thromboembolic events, major bleeding
BARC type III, rehospitalization, severe
symptoms due to arrhythmias
Recruiting November
2010
November 2013
Catheter ablation
of AF
PLACE III 100 LARIAT suture delivery
device and
accessories
AF Single group
assignment
Rate of complete exclusion Not yet
recruiting
September
2012
March 2014
Exclusion of the Left Atrial
Appendage (LAA) with the
TigerPaw System (LAAx Inc)
60 Device: LAAx TigerPaw
System
Stroke Safety/efﬁcacy study Dual primary safety and effectiveness
outcomes including rate of device-
related adverse and serious adverse
events and extent of complete exclusion
of LAA with minimal residual cavity
Recruiting August 2009 October 2010
LAAOSII 50 Surgical occlusion of
LAA
AF and stroke Randomized Demonstration of efﬁcacy of cut-and-sew
and stapler technique of appendage
occlusion by intraoperative
transesophageal echocardiography,
central adjudication
Recruiting August 2009 October 2013
Best medical practice
for AF/stroke
prevention per
guidelines
Atrial and Brain Natriuretic
Peptide Secretion After
Percutaneous Closure of the
Left Atrial Appendage
50 WATCHMAN LAA
closure technology
AF and stroke Efﬁcacy study Change from baseline plasma ANP and
BNP levels after transcatheter closure of
LAA
Not yet
recruiting
May 2010 January 2012
AMPLATZER Cardiac Plug Clinical
Trial
3000 Device: AMPLATZER
cardiac plug
Active comparator:
Optimal medical
therapy (control)
AF Randomized Acute safety
Long-term safety
Effectiveness end-point: Occurrence of
ischemic stroke and peripheral
thromboembolism
Recruiting May 2010 June 2017
Left Atrial Appendage (LAA)
Occluders After Catheter
Ablation of Atrial Fibrillation
40 Device: LAA occlusion
Procedure:
Radiofrequency
ablation
AF Randomized All stroke, systemic embolism,
cardiovascular death
Recruiting December
2011
December 2013
Safety and Effectiveness of Left
Atrial Appendage Occlusion
37 AtriCure LAA exclusion
system
AF Safety/efﬁcacy
study
Safety: Device-related complications
Efﬁcacy: LAA occlusion
Not yet
recruiting
September
2007
September 2012
AF ¼ atrial ﬁbrillation; ANP ¼ atrial natriuretic peptide; BARC = Bleeding Academic Research Consortium; BNP ¼ brain natriuretic peptide; LAA ¼ left atrial appendage.
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Heart Rhythm, Vol 11, No 3, March 2014520patients who must discontinue OAC treatment because of
major bleeding. Patients who already have a documented
history of major gastrointestinal bleeding or hemorrhagic
stroke but have a high thromboembolic risk and ischemic
patients with AF treated with drug-eluting stent who require
triple antithrombotic therapy can be considered for this
alternative option. The schematic chart shown in Figure 5
summarizes the main cases when LAAC alternative can be
evaluated.What next?
Any intervention that successfully prevents stroke will have
a large impact on clinical practice and the health care system.
Device therapy must be carefully considered, but there is still
much to be done in order to understand the full value of this
approach. It is crucial to know how many strokes can be
prevented by excluding the LAA and which patients might
beneﬁt most from this procedure.
Table 2 lists the 11 LAA occlusion/excision trials that are
ongoing. It demonstrates the high interest in this topic and
the large volume of additional data needed to fully under-
stand the phenomenon of clot formation and the best
solutions for stroke prevention.
Studies comparing LAAC against the new direct OACs
and against placebo in patients who cannot tolerate any form
of anticoagulation must also be considered in order to
complete the development of this therapy. Other studies will
involve new designs of such devices and the systems
developed to deliver them safely to the left atrial appendage.
At the present time, the evidence base on LAAC supports
the use of LA occlusion in those patients who cannot be
treated long term with OAC. The current ESC guidelines on
AF management recommend that percutaneous LAAC “may
be considered in patients with a high stroke risk and
contraindications for long-term oral anticoagulation.” The
cited level of evidence is “B.” Although there is ample
evidence of the value of device implantation in patients who
can tolerate warfarin in order for the comparison to be made,
there is only limited information relevant to patients refrac-
tory to or incapable of taking oral anticoagulants, and it is
this latter group in which the unmet clinical need is dire and
toward which the guideline recommendation was directed.Acknowledgments
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